- Home
- PBYI vs LTBR Comparison
PBYI vs LTBR Comparison
Compare PBYI & LTBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- LTBR
- Stock Information
- Founded
- PBYI 2010
- LTBR 1992
- Country
- PBYI United States
- LTBR United States
- Employees
- PBYI N/A
- LTBR N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- LTBR Professional Services
- Sector
- PBYI Health Care
- LTBR Consumer Discretionary
- Exchange
- PBYI Nasdaq
- LTBR Nasdaq
- Market Cap
- PBYI 152.4M
- LTBR 156.6M
- IPO Year
- PBYI N/A
- LTBR N/A
- Fundamental
- Price
- PBYI $3.28
- LTBR $15.05
- Analyst Decision
- PBYI Strong Buy
- LTBR
- Analyst Count
- PBYI 1
- LTBR 0
- Target Price
- PBYI $7.00
- LTBR N/A
- AVG Volume (30 Days)
- PBYI 375.3K
- LTBR 2.4M
- Earning Date
- PBYI 05-08-2025
- LTBR 05-12-2025
- Dividend Yield
- PBYI N/A
- LTBR N/A
- EPS Growth
- PBYI 143.51
- LTBR N/A
- EPS
- PBYI 0.77
- LTBR N/A
- Revenue
- PBYI $232,709,000.00
- LTBR N/A
- Revenue This Year
- PBYI N/A
- LTBR N/A
- Revenue Next Year
- PBYI N/A
- LTBR N/A
- P/E Ratio
- PBYI $4.25
- LTBR N/A
- Revenue Growth
- PBYI 2.68
- LTBR N/A
- 52 Week Low
- PBYI $2.23
- LTBR $2.21
- 52 Week High
- PBYI $4.13
- LTBR $17.70
- Technical
- Relative Strength Index (RSI)
- PBYI 52.36
- LTBR 69.38
- Support Level
- PBYI $3.14
- LTBR $9.82
- Resistance Level
- PBYI $3.45
- LTBR $17.70
- Average True Range (ATR)
- PBYI 0.19
- LTBR 1.52
- MACD
- PBYI 0.01
- LTBR 0.50
- Stochastic Oscillator
- PBYI 51.19
- LTBR 67.48
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.